Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tells you everything you need to know, right at the top of the document:
"Industry
Pharmaceutical products - 33600000
Various medicinal products - 33690000"
Absolutely agree alf, no way can our dietary supplement meet the criteria for supplying the NHS with anticoags, however good we might think it is. This is strictly warfarin territory IMHO.
Wouldn't get too excited about that one, absolutely no chance of any bid to supply a non drug dietary supplement for that use IMHO
Rpg7
Where did you see that published?
rpg,
So could PXS/DSM bid for supplying Fruitflow?
NHS Framework Agreement for the supply of Direct Oral Anticoagulants (DOACs) for the NHS in England.
Open opportunity -This means that the contract is currently active, and the buying department is looking for potential suppliers to fulfil the contract.
Value of contract £3,185,000,000
Published date 22nd July 2021
Closing date 3rd September 2021
"Fruitflow Proven to Prevent Platelet Aggression, Can Be Used to Reduce Covid-19 Death Risk"
https://www.wartaekonomi.co.id/read352526/fruitflow-terbukti-cegah-agresi-trombosit-bisa-dimanfaatkan-untuk-tekan-risiko-kematian-covid-19
Dr_H, I believe that was more to do with the commercial terms of the Alliance Agreement rather than extending it. Remember "The Company's Alliance Agreement with DSM Nutritional Products for Fruitflow® includes a financial model which is based upon the division of profits between the two partners on an agreed basis, linked to certain revenue targets, following the deduction of the cost of goods and a fixed level of overhead from sales."
The the fixed level of overheads from sales was reduced at the time.
https://www.investegate.co.uk/provexis-plc--pxs-/rns/enhanced-terms-for-fruitflow-alliance-agreement/201506040700321648P/
Ah ok. Shame, maybe see you at the AGM
Kiev
just a flyby, picked the old man up and took him back to us. Too much CV still about for him
WS
Just realized it's around the time you were coming to Strou. Are you still coming
Hi Gixer, thanks for the info. And yes would love to be a fly on the wall for that meeting/s. When/if bi-health get blue cap status by then we will certainly have the upper hand. I got to agree with CB DSM have been useless but we have to thank them for the powder format.
Kievs
DSM certainly haven't covered themselves in glory, I recall it was mentioned in an update it was acknowledged DSM lost focus. That said, I don't think the delay was all down to DSM...
: Previous CEO's SIS vanity project cost us a few years
: Patent approvals taken longer than we had anticipated
We have never had sight of a business plan for the company. We get the odd snippet of what to expect (with no timeline - Bluecap, nitrates, USA launch). More collaborations, more studies, blah blah blah. Certainly feels like a lifestyle company.
The Prof is rolled out to give what I find to be very garbled presentations (I understood Vanto better than I do the Prof). Why isn't Niamh out there doing the presenting ? She has the qualifications and has excellent presentation skills and clearly understand the concept of less is more.
That said, I think/hope we are in the best place we have ever been in. I wonder how many of the Chinese Olympic team are taking FF+ nitrates. I for one would support SL getting a seat on the board....
W$
(trip south cut to a flying visit, so no time for a beer - next time when CV isn't still hanging around)
Re the 2022 renegotiation. Didn’t we already renegotiate improved terms for PXS a couple of years ago?
11 years later and the SP is less than a penny and all the charts make for grim reading. I wonder if DSM still regard FF as the "jewel in the crown" etc etc. We weren't half fed some rubbish and still no clear path forward with too much reliance on the Chinese to save the day.
"The Company announced on 1 June 2010 that it had entered into a long-term alliance with DSM to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications (the "Alliance"). Strategy, co-ordination, organisation and implementation for the Alliance is governed by an Alliance Board comprising two members from each partner company. The agreement extends initially until 2022 at which time the partners will review the arrangement. DSM will put substantial efforts into the Alliance and will be responsible for: manufacturing; marketing; and selling Fruitflow® via its substantial sales force. Provexis will be responsible for contributing scientific expertise necessary for the successful commercialisation of the product."
https://www.investegate.co.uk/provexis-plc--pxs-/rns/interim-results/201012160700080528Y/
Would like to be a fly on the wall during the review but any renegotiations should be in our favour IMO.
So much information on how good Fruitflow is. Even helps towards Covid-19 yet DSM still cant bag a major or Global. I am sure Bi-Health will do the business for us. Gixer, when is our deal with DSM ending
Not going to go through all FF products but this is what Zaax says.
"Healthy blood flow during the COVID-19 epidemic
The problems related to the COVID-19 epidemic concern not only the disease itself, but also other areas of the drowia, especially the cardiovascular system. Isolation, limited movement, less access to health care or tress, can negatively affect platelet aggregation and disrupt proper circulation .
Maintaining healthy blood flow during an epidemic is particularly important in those who may have been at risk of blood flow disorders before the pandemic, and in all healthy people who have had COVID-19 and all who are at risk of falling ill."
https://zaax.com.pl/
"During the COVID-19 epidemic, good blood flow should be ensured by the above-mentioned people and:
healthy people who have had COVID-19
all those who are at risk of falling ill"
https://sequoia.pl/product/zaax/
"Who is to say European products couldn't focus there advertising on maintaining normal platelet aggregation before or during initial or mild infection as a benefit of Fruitflow?"
should read
Who is to say European products couldn't focus there advertising on maintaining normal platelet aggregation before or during initial or mild infection as a potential benefit of Fruitflow?
Duttaroy says in his reply.
"The potential impact of the platelet in infection has only recently really come to the forefront of attention, and so although there are some studies currently in the planning stage, we do not have much to reference here yet."
Sounds like they are on the case.
alfista, "demonstrate that there is a long way to go before any health claim could be established" I don't disagree but all countries don't have such a stringent regulatory body as Europe or China.
AFC Life science in Indonesia, with there recent seminars, are obviously happy to make the health benefit connection to Fruitflow and Covid-19. Not only AFC but Biogrow with SmoFlo in Malaysia are also able to say that platelet aggregation due to Covid-19 could be reduced and help avoid unwanted blood clots with the use of Fruitflow.
https://biogrow.com.my/smoflo-capsule/trial-program
Its all above my pay grade but Fruitflow already has the health claim "Helps maintain normal platelet aggregation, which contributes to healthy blood flow" and Covid-19 has been proven to activate platelets and cause blood clots.
2+2=?
Who is to say European products couldn't focus there advertising on maintaining normal platelet aggregation before or during initial or mild infection as a benefit of Fruitflow?
Saying that, I doubt we will see it any time soon.
The reviewer's response, and replies to the reviewer, demonstrate that there is a long way to go before any health claim could be established. Set against this , seminars talking about the health claims have happened. If we are waiting for a new branch of Fruitflow benefits to be confirmed, the wait could be substantial IMHO. Better to concentrate on established claims for the time being.
wellsite, not sure what you mean by "presented" but it was first released as a "preprint"and not peer-reviewed April 2021.
https://www.preprints.org/manuscript/202104.0039/v1/download
Then published as a review paper in Nutrients journal: 25 June 2021
https://www.mdpi.com/2072-6643/13/7/2184/pdf
Peer-Review Record
https://www.mdpi.com/2072-6643/13/7/2184/review_report
Re "do you think PXS are in talks to sell up?"
No, raising a million in a placing doesn't square up with the idea of actively looking to sell up, quite the opposite.
Plainly if someone came along with a really good offer, that'd be something to consider, so never say never, but that's very different to actively looking to sell up
BB